Literature DB >> 10691849

Intracellular accumulation of factor VIII induced by missense mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting material-reduced haemophilia A.

J C Roelse1, R T De Laaf, S M Timmermans, M Peters, J A Van Mourik, J Voorberg.   

Abstract

Patients with cross-reacting material (CRM)-reduced haemophilia A exhibit reduced levels of factor VIII antigen. In this study, we determined the molecular basis of the genetic defect in the factor VIII gene induced by either the Arg593-->Cys or the Asn618-->Ser missense mutation, identified in two CRM-reduced haemophilia A patients. We introduced either the Arg593-->Cys or the Asn618-->Ser mutation into a B-domain-deleted factor VIII cDNA and expressed the modified cDNAs in C127 cells. Reduced levels of factor VIII activity and factor VIII antigen in conditioned medium of transfected cells indicated that the secretion of both factor VIII variants was impaired. The ratio of factor VIII antigen present in cell extract to that in conditioned medium was 1.9 and 2.4 times higher for rFVIII-R593C and rFVIII-N618S, respectively, than for rFVIII. Metabolic labelling and immunoprecipitation of transfected cells revealed that rFVIII-R593C and rFVIII-N618S persisted somewhat longer inside the cell than factor rFVIII. Intracellular accumulation and subsequent degradation of factor VIII-R593C and factor VIII-N618S may explain the reduced levels of both factor VIII activity and antigen in plasma of mild haemophilia A patients with corresponding genetic defects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691849     DOI: 10.1046/j.1365-2141.2000.01834.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.

Authors:  David W Scott; Jay N Lozier
Journal:  Br J Haematol       Date:  2011-11-07       Impact factor: 6.998

Review 2.  Haemophilia A and haemophilia B: molecular insights.

Authors:  D J Bowen
Journal:  Mol Pathol       Date:  2002-04

3.  Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

Authors:  Ryan J Summers; Shannon L Meeks; John F Healey; Harrison C Brown; Ernest T Parker; Christine L Kempton; Christopher B Doering; Pete Lollar
Journal:  Blood       Date:  2011-01-07       Impact factor: 22.113

Review 4.  Haemophilia A and haemophilia B: molecular insights.

Authors:  D J Bowen
Journal:  Mol Pathol       Date:  2002-02

Review 5.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

6.  Specific and global coagulation tests in patients with mild haemophilia A with a double mutation (Glu113Asp, Arg593Cys).

Authors:  Alenka Trampuš Bakija; Maruša Debeljak; Irena Preložnik Zupan; Majda Benedik Dolničar; Jernej Kovač; Janez Jazbec
Journal:  Blood Transfus       Date:  2015-05-15       Impact factor: 3.443

7.  Antioxidants reduce endoplasmic reticulum stress and improve protein secretion.

Authors:  Jyoti D Malhotra; Hongzhi Miao; Kezhong Zhang; Anna Wolfson; Subramaniam Pennathur; Steven W Pipe; Randal J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

8.  Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites.

Authors:  Adoración Venceslá; María Angeles Corral-Rodríguez; Manel Baena; Mónica Cornet; Montserrat Domènech; Montserrat Baiget; Pablo Fuentes-Prior; Eduardo F Tizzano
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

9.  In silico profiling of deleterious amino acid substitutions of potential pathological importance in haemophlia A and haemophlia B.

Authors:  George Priya Doss C
Journal:  J Biomed Sci       Date:  2012-03-16       Impact factor: 8.410

10.  Mutations in intron 1 and intron 22 inversion negative haemophilia A patients from Western India.

Authors:  Preethi S Nair; Shrimati D Shetty; S Chandrakala; Kanjaksha Ghosh
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.